Protease-sparing regimen
| Protease-sparing regimen | |
|---|---|
| Other names | PSR |
| Specialty | virology |
Protease-sparing regimen, often abbreviated as PSR, is a method or therapy for treating people infected with HIV that involves a three-drug combination that reduces viral load below the limit of detection while saving protease inhibitors for later use. It is considered a weaker (in terms of quantity and concentration) form of HIV treatment. It has been argued that such a regimen is not as potent as giving HIV patients with the strongest drugs as soon as it is detected. Others believe that this might be considered a long-term strategy in order to reduce the amount of HIV,[1] and in some instances have proven to be successful.[2]
See also
- Protease
- Women's Interagency HIV Study
References
- ↑ Corales RB, Shrestha NK, Taege AJ, et al. (2001). "Protease-sparing regimen in a real-life practice with naïve patients: an equal opportunity approach?". HIV Clin Trials. 2 (1): 17–21. doi:10.1310/2V0B-HDWC-AGWR-H56M. PMID 11590510. S2CID 26663673.
- ↑ Van der Linden D, Hainaut M, Goetghebuer T, et al. (April 2007). "Effectiveness of early initiation of protease inhibitor-sparing antiretroviral regimen in human immunodeficiency virus-1 vertically infected infants". Pediatr. Infect. Dis. J. 26 (4): 359–61. doi:10.1097/01.inf.0000258626.34984.eb. hdl:2078/119175. PMID 17414406. S2CID 74548567.
External links
- "Protease Sparing Regimen in a Real Life Practice with Naive Patients: An Equal Opportunity Approach?". 13th International AIDS Conference. Durban, South Africa. July 9–14, 2000. WePeB4134. Archived from the original on 2007-09-30. Retrieved 2007-04-17.
- http://www.aids-ed.org/aidsetc?page=et-14-00-02
- http://www.medscape.com/viewarticle/418668
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.